Refractory Malignant Solid Neoplasm Clinical Trials

10 recruiting

Refractory Malignant Solid Neoplasm Trials at a Glance

10 actively recruiting trials for refractory malignant solid neoplasm are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 10 trials, with the heaviest enrollment activity in Los Angeles, Memphis, and Atlanta. Lead sponsors running refractory malignant solid neoplasm studies include Children's Oncology Group, City of Hope Medical Center, and Anusha Kalbasi.

Browse refractory malignant solid neoplasm trials by phase

Treatments under study

About Refractory Malignant Solid Neoplasm Clinical Trials

Looking for clinical trials for Refractory Malignant Solid Neoplasm? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Refractory Malignant Solid Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Refractory Malignant Solid Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Locally Advanced Pancreatic CarcinomaMetastatic Pancreatic CarcinomaStage II Pancreatic Cancer AJCC v8+6 more
National Cancer Institute (NCI)49 enrolled3 locationsNCT05053971
Recruiting
Phase 1Phase 2

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1

MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers

Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm
Mayo Clinic42 enrolled1 locationNCT06911008
Recruiting
Phase 1

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

Breast CancerHead and Neck Squamous Cell CarcinomaMetastatic Malignant Solid Neoplasm+14 more
Anusha Kalbasi18 enrolled3 locationsNCT04119024
Recruiting
Phase 1Phase 2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Lymphoma+7 more
Children's Oncology Group63 enrolled34 locationsNCT04870944
Recruiting
Phase 1Phase 2

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1Phase 2

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRefractory Childhood Malignant Solid Neoplasm+6 more
Children's Oncology Group81 enrolled20 locationsNCT06620302
Recruiting
Phase 1

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Stage III Hepatocellular Carcinoma AJCC v8Stage IV Hepatocellular Carcinoma AJCC v8Refractory Malignant Solid Neoplasm+4 more
University of Southern California36 enrolled2 locationsNCT05791448
Recruiting
Phase 1Phase 2

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

Metastatic Malignant Solid NeoplasmRecurrent Malignant Solid NeoplasmRefractory Malignant Solid Neoplasm+1 more
OHSU Knight Cancer Institute38 enrolled1 locationNCT06320405
Recruiting
Phase 1

AOH1996 for the Treatment of Refractory Solid Tumors

Ovarian CancerRefractory Malignant Solid NeoplasmOsteosarcoma+2 more
City of Hope Medical Center92 enrolled2 locationsNCT05227326